Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report) today and set a price target of $62.00. The company’s shares closed yesterday at $24.72.
Tenthoff covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Arrowhead Pharmaceuticals, and Opko Health. According to TipRanks, Tenthoff has an average return of -1.6% and a 35.35% success rate on recommended stocks.
Currently, the analyst consensus on Arrowhead Pharmaceuticals is a Strong Buy with an average price target of $56.40, representing a 128.16% upside. In a report released yesterday, RBC Capital also maintained a Buy rating on the stock with a $50.00 price target.
The company has a one-year high of $40.89 and a one-year low of $20.67. Currently, Arrowhead Pharmaceuticals has an average volume of 1.2M.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ARWR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arrowhead Pharmaceuticals (ARWR) Company Description:
Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
Read More on ARWR:
